ifosfamide has been researched along with Anemia in 27 studies
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 9.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 9.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 9.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 7.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 7.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 7.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 5.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 5.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 5.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 3.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 3.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded." | 3.78 | Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 3.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| "Ifosfamide was administered at a fixed dose of 1." | 2.71 | Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004) |
| "Grade 3 thrombocytopenia was observed in five cases (36%)." | 2.71 | Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005) |
| "Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients." | 2.71 | Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005) |
| "Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna." | 2.70 | Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001) |
| "Fever is a very rare presentation of splenic angiosarcoma." | 2.52 | Primary splenic angiosarcoma with fever and anemia: a case report and literature review. ( Chang, W; Chen, J; Deng, R; Tao, K; Wu, X; Zhang, P, 2015) |
| "Ifosfamide is an alkylating agent which has poorly understood toxic side effects such as encephalopathy." | 1.30 | Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. ( Baerlocher, GM; Beer, JH; Cerny, T; Meiselman, HJ; Owen, GR; Reinhart, WH, 1999) |
| "Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo." | 1.27 | Ifosfamide in advanced pancreatic cancer. A 5-year experience. ( Gad-el-Mawla, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, W | 1 |
| Shi, M | 1 |
| Yang, J | 2 |
| Cao, J | 1 |
| Xu, L | 1 |
| Yan, D | 1 |
| Yao, M | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Sun, K | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Jiao, J | 1 |
| Qin, Y | 2 |
| Sang, T | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Gao, X | 1 |
| Cheng, H | 1 |
| Yan, Z | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Zhu, F | 1 |
| Wang, Y | 1 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Zheng, J | 1 |
| Xu, K | 1 |
| Blay, JY | 1 |
| Leahy, MG | 1 |
| Nguyen, BB | 1 |
| Patel, SR | 1 |
| Hohenberger, P | 1 |
| Santoro, A | 1 |
| Staddon, AP | 1 |
| Penel, N | 1 |
| Piperno-Neumann, S | 1 |
| Hendifar, A | 1 |
| Lardelli, P | 1 |
| Nieto, A | 1 |
| Alfaro, V | 1 |
| Chawla, SP | 1 |
| Kakutani, S | 1 |
| Fukuhara, H | 1 |
| Taguchi, S | 1 |
| Nagata, M | 1 |
| Niimi, A | 1 |
| Hattori, M | 1 |
| Miyazaki, H | 1 |
| Fujimura, T | 1 |
| Nakagawa, T | 1 |
| Kume, H | 2 |
| Igawa, Y | 1 |
| Homma, Y | 1 |
| Yin, ZM | 1 |
| Yu, AJ | 1 |
| Wu, MJ | 1 |
| Fang, J | 1 |
| Liu, LF | 1 |
| Zhu, JQ | 1 |
| Yu, H | 1 |
| Hu, S | 1 |
| He, X | 1 |
| Dong, M | 1 |
| Jia, B | 1 |
| Zhou, S | 1 |
| Yang, S | 1 |
| Zhang, C | 1 |
| Liu, P | 1 |
| Gui, L | 1 |
| Deng, R | 1 |
| Chang, W | 1 |
| Wu, X | 1 |
| Chen, J | 1 |
| Tao, K | 1 |
| Zhang, P | 1 |
| Lee, AC | 1 |
| Abu-Khalaf, MM | 1 |
| Raza, MA | 1 |
| Hatzis, C | 1 |
| Wang, H | 1 |
| Lin, K | 1 |
| Higgins, S | 1 |
| Ratner, E | 1 |
| Silasi, DA | 1 |
| Azodi, M | 1 |
| Rutherford, TJ | 1 |
| Santin, AD | 1 |
| Schwartz, PE | 1 |
| Coriat, R | 1 |
| Mir, O | 1 |
| Camps, S | 1 |
| Ropert, S | 1 |
| Billemont, B | 1 |
| Leconte, M | 1 |
| Larousserie, F | 1 |
| Anract, P | 1 |
| Alexandre, J | 1 |
| Goldwasser, F | 1 |
| Motomura, K | 1 |
| Natsume, A | 1 |
| Fujii, M | 1 |
| Ito, M | 1 |
| Momota, H | 1 |
| Wakabayashi, T | 1 |
| Gupta, AA | 1 |
| Anderson, JR | 1 |
| Pappo, AS | 1 |
| Spunt, SL | 1 |
| Dasgupta, R | 1 |
| Indelicato, DJ | 1 |
| Hawkins, DS | 1 |
| Kerbusch, T | 1 |
| Groenewegen, G | 1 |
| Mathôt, RA | 1 |
| Herben, VM | 1 |
| ten Bokkel Huinink, WW | 1 |
| Swart, M | 1 |
| Ambaum, B | 1 |
| Rosing, H | 1 |
| Jansen, S | 1 |
| Voest, EE | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Worden, FP | 1 |
| Taylor, JM | 1 |
| Biermann, JS | 1 |
| Sondak, VK | 1 |
| Leu, KM | 1 |
| Chugh, R | 1 |
| McGinn, CJ | 1 |
| Zalupski, MM | 1 |
| Baker, LH | 1 |
| Takahashi, S | 1 |
| Suzuki, M | 1 |
| Matsumoto, S | 1 |
| Okamoto, N | 1 |
| Nishimatsu, H | 1 |
| Tomita, K | 1 |
| Kitamura, T | 1 |
| Lorusso, V | 1 |
| Gebbia, V | 1 |
| Spada, M | 1 |
| Guida, M | 1 |
| Cassano, G | 1 |
| Brunetti, C | 1 |
| Germano, D | 1 |
| Nettis, G | 1 |
| Izzi, G | 1 |
| Galetta, D | 1 |
| Giampaglia, M | 1 |
| Silvestris, N | 1 |
| Colucci, G | 1 |
| Su, Y | 1 |
| Hartlapp, JH | 1 |
| Jaeger, N | 1 |
| Fischer, P | 1 |
| Weissbach, L | 1 |
| de Campos, E | 1 |
| Radford, J | 1 |
| Steward, W | 1 |
| Milroy, R | 1 |
| Dougal, M | 1 |
| Swindell, R | 1 |
| Testa, N | 1 |
| Thatcher, N | 1 |
| Rao, SP | 1 |
| Miller, ST | 1 |
| Cohen, BJ | 1 |
| Lokich, J | 1 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Dow, E | 1 |
| Hempling, RE | 1 |
| Eltabbakh, GH | 1 |
| Piver, MS | 1 |
| Recio, FO | 1 |
| O'Neill, CP | 1 |
| Zarogoulidis, K | 1 |
| Papagiannis, A | 1 |
| Ziogas, E | 1 |
| Fahantidou, E | 1 |
| Dermitzakis, G | 1 |
| Gioulekas, D | 1 |
| Vamvalis, C | 1 |
| De Pas, T | 1 |
| De Braud, F | 1 |
| Orlando, L | 1 |
| Nolè, F | 1 |
| Munzone, E | 1 |
| Zampino, MG | 1 |
| Fazio, N | 1 |
| Aapro, MS | 1 |
| Goldhirsch, A | 1 |
| Reinhart, WH | 1 |
| Baerlocher, GM | 1 |
| Cerny, T | 1 |
| Owen, GR | 1 |
| Meiselman, HJ | 1 |
| Beer, JH | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Pectasides, D | 1 |
| Aravantinos, G | 1 |
| Kalofonos, H | 1 |
| Kiamouris, C | 1 |
| Bafaloukos, D | 1 |
| Xiros, N | 1 |
| Nicolaides, C | 1 |
| Visvikis, A | 1 |
| Dimopoulos, MA | 1 |
| Gad-el-Mawla, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120] | Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 66.7 |
| Doxorubicin Plus Ifosfamide | 78.3 |
The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months
| Intervention | days (Median) |
|---|---|
| Trabectedin | NA |
| Doxorubicin Plus Ifosfamide | NA |
Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)
| Intervention | months (Median) |
|---|---|
| Trabectedin | 46.6 |
| Doxorubicin Plus Ifosfamide | 33.5 |
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 5.9 |
| Doxorubicin Plus Ifosfamide | 27.0 |
The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months
| Intervention | months (Median) |
|---|---|
| Trabectedin | 19.6 |
| Doxorubicin Plus Ifosfamide | 8.3 |
1 review available for ifosfamide and Anemia
| Article | Year |
|---|---|
Primary splenic angiosarcoma with fever and anemia: a case report and literature review.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Chemotherapy, Adj | 2015 |
14 trials available for ifosfamide and Anemia
| Article | Year |
|---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R | 2020 |
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm | 2014 |
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S | 2010 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D | 2004 |
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2005 |
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo | 2005 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small- | 2005 |
[Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].
Topics: Adult; Alopecia; Anemia; Bleomycin; Ceruletide; Cisplatin; Constipation; Cyclophosphamide; Drug Ther | 1982 |
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small C | 1995 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che | 1996 |
The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1997 |
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib | 1998 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He | 2001 |
12 other studies available for ifosfamide and Anemia
| Article | Year |
|---|---|
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce | 2015 |
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendo | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid | 2015 |
A Child with Rapid-onset Respiratory Distress after Chemotherapy, Lung Irriadiation, General Anaesthesia, and Blood Transfusion.
Topics: Abdominal Neoplasms; Acute Lung Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chil | 2015 |
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap | 2016 |
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Sy | 2011 |
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2012 |
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubi | 2006 |
B19 parvovirus infection in children with malignant solid tumors receiving chemotherapy.
Topics: Acute Disease; Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chil | 1994 |
Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Erythrop | 1997 |
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood.
Topics: Adult; Anemia; Antineoplastic Agents, Alkylating; Cell Aggregation; Erythrocyte Deformability; Eryth | 1999 |
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middl | 1986 |